Is Lixte Biotechnology Holdings Inc (LIXT) a Poor Choice in the Healthcare Sector?

A rating of 14 puts Lixte Biotechnology Holdings Inc (LIXT) near the top of the Healthcare sector according to InvestorsObserver. Lixte Biotechnology Holdings Inc's score of 14 means that it ranks higher than 14% of stocks in the sector. In addition, its overall score of 20 ranks it higher than 20% of all stocks.

LIXT has an Overall Score of 20. Find out what this means to you and get the rest of the rankings on LIXT!

See Full LIXT Report

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. *Investors Observer* makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in healthcare or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Lixte Biotechnology Holdings Inc Stock Today?

Lixte Biotechnology Holdings Inc (LIXT) stock is higher by 1.08% while the S&P 500 is down -0.11% as of 10:07 AM on Monday, Sep 25. LIXT is up $0.02 from the previous closing price of $1.86 on volume of 2,984 shares. Over the past year the S&P 500 has risen 18.07% while LIXT is down -68.08%. LIXT lost -$3.69 per share the over the last 12 months. Click Here to get the full Stock Report for Lixte Biotechnology Holdings Inc stock.